|
PT1993360T
(pt)
|
2005-12-28 |
2017-05-25 |
Vertex Pharma |
Formas sólidas de n-[2,4-bis(1,1-dimetiletil)-5-hidroxifenil]-1,4-di-hidro-4-oxoquinolina-3-carboxamida
|
|
MX358640B
(es)
|
2008-01-04 |
2018-08-29 |
Intellikine Llc |
Isoquinolin-1 (2h) -onas y tieno [2,3-d]pirimidin-4(3h) -onas substituidas, y metodos de uso de las mismas.
|
|
US8193182B2
(en)
|
2008-01-04 |
2012-06-05 |
Intellikine, Inc. |
Substituted isoquinolin-1(2H)-ones, and methods of use thereof
|
|
HRP20140754T2
(hr)
|
2009-06-29 |
2015-07-17 |
Incyte Corporation |
Pirimidinoni kao inhibitori pi3k
|
|
US8759359B2
(en)
|
2009-12-18 |
2014-06-24 |
Incyte Corporation |
Substituted heteroaryl fused derivatives as PI3K inhibitors
|
|
EP2552208A4
(en)
*
|
2010-03-31 |
2014-07-09 |
Glaxo Group Ltd |
IMIDAZOLYL-IMIDAZOLES AS KINASE INHIBITORS
|
|
WO2011130342A1
(en)
|
2010-04-14 |
2011-10-20 |
Incyte Corporation |
FUSED DERIVATIVES AS ΡI3Κδ INHIBITORS
|
|
US9062055B2
(en)
|
2010-06-21 |
2015-06-23 |
Incyte Corporation |
Fused pyrrole derivatives as PI3K inhibitors
|
|
WO2012080729A2
(en)
*
|
2010-12-14 |
2012-06-21 |
Electrophoretics Limited |
CASEIN KINASE 1δ (CK1δ) INHIBITORS
|
|
WO2012087881A1
(en)
|
2010-12-20 |
2012-06-28 |
Incyte Corporation |
N-(1-(substituted-phenyl)ethyl)-9h-purin-6-amines as pi3k inhibitors
|
|
US8754114B2
(en)
|
2010-12-22 |
2014-06-17 |
Incyte Corporation |
Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3
|
|
TWI546305B
(zh)
|
2011-01-10 |
2016-08-21 |
英菲尼提製藥股份有限公司 |
製備異喹啉酮之方法及異喹啉酮之固體形式
|
|
WO2012125629A1
(en)
|
2011-03-14 |
2012-09-20 |
Incyte Corporation |
Substituted diamino-pyrimidine and diamino-pyridine derivatives as pi3k inhibitors
|
|
GB201104267D0
(en)
|
2011-03-14 |
2011-04-27 |
Cancer Rec Tech Ltd |
Pyrrolopyridineamino derivatives
|
|
WO2012135009A1
(en)
|
2011-03-25 |
2012-10-04 |
Incyte Corporation |
Pyrimidine-4,6-diamine derivatives as pi3k inhibitors
|
|
AR087701A1
(es)
|
2011-08-31 |
2014-04-09 |
Japan Tobacco Inc |
Derivados de pirazol con actividad inhibidora de sglt1
|
|
LT3196202T
(lt)
|
2011-09-02 |
2019-07-10 |
Incyte Holdings Corporation |
Heterociklilaminai, kaip pi3k slopikliai
|
|
JP6117191B2
(ja)
|
2011-10-07 |
2017-04-19 |
武田薬品工業株式会社 |
神経変性疾患の治療に有用な１−アリールカルボニル−４−オキシ−ピペリジン化合物
|
|
MX344014B
(es)
|
2011-10-18 |
2016-12-02 |
Astellas Pharma Inc |
Compuesto heterocíclico bicíclico.
|
|
AR090037A1
(es)
|
2011-11-15 |
2014-10-15 |
Xention Ltd |
Derivados de tieno y/o furo-pirimidinas y piridinas inhibidores de los canales de potasio
|
|
ES2652664T3
(es)
|
2011-12-01 |
2018-02-05 |
Chemocentryx, Inc. |
Anilinas sustituidas como antagonistas de CCR(4)
|
|
AR090548A1
(es)
|
2012-04-02 |
2014-11-19 |
Incyte Corp |
Azaheterociclobencilaminas biciclicas como inhibidores de pi3k
|
|
PE20190736A1
(es)
|
2012-06-13 |
2019-05-23 |
Incyte Holdings Corp |
Compuestos triciclicos sustituidos como inhibidores del receptor del factor de crecimiento de fibroblastos (fgfr)
|
|
PT2861566T
(pt)
|
2012-06-13 |
2017-02-08 |
Hoffmann La Roche |
Novos diazaspirocicloalcanos e azaspirocicloalcanos
|
|
US8828998B2
(en)
|
2012-06-25 |
2014-09-09 |
Infinity Pharmaceuticals, Inc. |
Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
|
|
EP2871179A4
(en)
|
2012-07-03 |
2016-03-16 |
Ono Pharmaceutical Co |
CONNECTION WITH AGONISTIC EFFECT ON THE SOMATOSTATIN RECEPTOR AND ITS USE FOR MEDICAL PURPOSES
|
|
WO2014009891A1
(en)
*
|
2012-07-11 |
2014-01-16 |
Piramal Enterprises Limited |
Heterocyclic compounds for use in the treatment of cancers
|
|
WO2014026125A1
(en)
|
2012-08-10 |
2014-02-13 |
Incyte Corporation |
Pyrazine derivatives as fgfr inhibitors
|
|
US10208043B2
(en)
|
2012-08-22 |
2019-02-19 |
Cornell University |
Methods for inhibiting fascin
|
|
AU2013305663B2
(en)
*
|
2012-08-24 |
2017-11-02 |
Treventis Corporation |
Benzofurazan anti-amyloid compounds and methods
|
|
CN102850341B
(zh)
*
|
2012-09-05 |
2015-02-18 |
浙江工业大学 |
一种噻二唑类化合物及其制备与应用
|
|
GB201216018D0
(en)
|
2012-09-07 |
2012-10-24 |
Cancer Rec Tech Ltd |
Pharmacologically active compounds
|
|
AU2013322838B2
(en)
|
2012-09-25 |
2018-02-01 |
F. Hoffmann-La Roche Ag |
New bicyclic derivatives
|
|
CN103739594A
(zh)
*
|
2012-10-17 |
2014-04-23 |
南京大学 |
一类含吡嗪环和三氮唑结构的席夫碱类衍生物及其制法
|
|
CN105102000B
(zh)
|
2012-11-01 |
2021-10-22 |
无限药品公司 |
使用pi3激酶亚型调节剂的癌症疗法
|
|
BR112015011497B1
(pt)
|
2012-11-27 |
2023-01-10 |
Thomas Helledays Stiftelse För Medicinsk Forskning |
Composto, e, formulação farmacêutica
|
|
US9266892B2
(en)
|
2012-12-19 |
2016-02-23 |
Incyte Holdings Corporation |
Fused pyrazoles as FGFR inhibitors
|
|
EP2939675B1
(en)
*
|
2012-12-28 |
2019-09-04 |
Shin Nippon Biomedical Laboratories, Ltd. |
Oct3 activity inhibitor containing imidazopyridine derivative as active component, and oct3 detection agent
|
|
CA2900779C
(en)
|
2013-02-11 |
2021-10-26 |
The Regents Of The University Of California |
Compositions and methods for treating neurodegenerative diseases and cardiomyopathy
|
|
AR095079A1
(es)
|
2013-03-12 |
2015-09-16 |
Hoffmann La Roche |
Derivados de octahidro-pirrolo[3,4-c]-pirrol y piridina-fenilo
|
|
US9776996B2
(en)
|
2013-03-15 |
2017-10-03 |
Epizyme, Inc. |
Substituted 6,5-fused bicyclic heteroaryl compounds
|
|
US9790188B2
(en)
|
2013-03-15 |
2017-10-17 |
Whitehead Institute For Biomedical Research |
Benzimidazole derivatives and uses thereof
|
|
US9045477B2
(en)
*
|
2013-03-15 |
2015-06-02 |
Epizyme, Inc. |
Substituted 6,5-fused bicyclic heteroaryl compounds
|
|
KR102269032B1
(ko)
|
2013-04-19 |
2021-06-24 |
인사이트 홀딩스 코포레이션 |
Fgfr 저해제로서 이환식 헤테로사이클
|
|
US9797882B2
(en)
|
2013-07-09 |
2017-10-24 |
The Translational Genomics Research Institute |
Method of screening for a compound for inhibitory activity of FN14-tweak interaction
|
|
US9238034B2
(en)
*
|
2013-07-09 |
2016-01-19 |
The Translational Genomics Research Institute |
FN14 antagonists and therapeutic uses thereof
|
|
TWI649308B
(zh)
|
2013-07-24 |
2019-02-01 |
小野藥品工業股份有限公司 |
喹啉衍生物
|
|
GB201314452D0
(en)
|
2013-08-13 |
2013-09-25 |
Ostara Biomedical Ltd |
Embryo implantation
|
|
RU2570907C2
(ru)
*
|
2013-10-21 |
2015-12-20 |
Автономная Некоммерческая Организация "Научно-Исследовательский Центр Биотехнологии Антибиотиков И Других Биологически Активных Веществ "Биоан" |
Производные 3-ациламинопиридин-2(1h)-она, применимые как ингибиторы серин-треониновой протеинкиназы gsk3b в качестве лекарственных препаратов для лечения диабета ii типа.
|
|
MX2016006657A
(es)
|
2013-11-22 |
2016-10-12 |
CL BioSciences LLC |
Antagonistas de gastrina (por ejemplo, yf476, netazepido) para el tratamiento y prevencion de osteoporosis.
|
|
AU2014356583B2
(en)
|
2013-11-26 |
2019-02-28 |
F. Hoffmann-La Roche Ag |
New octahydro-cyclobuta (1,2-c;3,4-c')dipyrrol-2-yl
|
|
GB201321738D0
(en)
*
|
2013-12-09 |
2014-01-22 |
Ucb Pharma Sa |
Therapeutic Agents
|
|
CA2935944A1
(en)
|
2014-01-09 |
2015-07-16 |
The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone |
Substituted benzoxazine and related compounds
|
|
KR20160106622A
(ko)
|
2014-01-29 |
2016-09-12 |
글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 |
화합물
|
|
JP6474826B2
(ja)
|
2014-01-29 |
2019-02-27 |
グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ |
化合物
|
|
CA2939219C
(en)
|
2014-02-11 |
2023-02-28 |
Mitokinin Llc |
Compositions and methods using the same for treatment of neurodegenerative and mitochondrial disease
|
|
EP3105219B9
(en)
|
2014-02-13 |
2018-10-03 |
Incyte Corporation |
Cyclopropylamines as lsd1 inhibitors
|
|
DK3105226T3
(da)
|
2014-02-13 |
2019-10-14 |
Incyte Corp |
Cyclopropylaminer som lsd1-inhibitorer
|
|
US9527835B2
(en)
|
2014-02-13 |
2016-12-27 |
Incyte Corporation |
Cyclopropylamines as LSD1 inhibitors
|
|
PT3105218T
(pt)
|
2014-02-13 |
2019-12-05 |
Incyte Corp |
Ciclopropilaminas como inibidores de lsd1
|
|
CA2940144C
(en)
|
2014-02-20 |
2023-06-13 |
Cornell University |
Substituted indazol-3-yl derivatives and pharmaceutical compositions thereof useful as inhibitor of fascin
|
|
CA2977360C
(en)
*
|
2014-02-27 |
2022-09-27 |
Treventis Corporation |
Anti-amyloid compounds containing benzofurazan
|
|
AU2015238537B2
(en)
|
2014-03-26 |
2019-08-01 |
F. Hoffmann-La Roche Ag |
Bicyclic compounds as autotaxin (ATX) and lysophosphatidic acid (LPA) production inhibitors
|
|
WO2015144609A1
(en)
|
2014-03-26 |
2015-10-01 |
F. Hoffmann-La Roche Ag |
Condensed [1,4]diazepine compounds as autotaxin (atx) and lysophosphatidic acid (lpa) production inhibitors
|
|
CN106164059A
(zh)
*
|
2014-04-11 |
2016-11-23 |
爱默蕾大学 |
用天冬酰胺内肽酶（aep）抑制剂以及相关组合物对神经退行性疾病的治疗
|
|
WO2015160975A2
(en)
|
2014-04-16 |
2015-10-22 |
Infinity Pharmaceuticals, Inc. |
Combination therapies
|
|
US9840482B2
(en)
*
|
2014-04-19 |
2017-12-12 |
Sunshine Lake Pharma Co., Ltd. |
Sulfonamide derivatives and pharmaceutical applications thereof
|
|
JP6626449B2
(ja)
*
|
2014-04-23 |
2019-12-25 |
ダート・ニューロサイエンス・（ケイマン）・リミテッド |
ＰＤＥ２阻害剤としての置換［１，２，４］トリアゾロ［１，５−ａ］ピリミジン−７−イル化合物
|
|
EP3140298A1
(en)
|
2014-05-07 |
2017-03-15 |
Pfizer Inc. |
Tropomyosin-related kinase inhibitors
|
|
CN104059060B
(zh)
*
|
2014-05-30 |
2017-08-01 |
西安交通大学 |
一种5‑(1h‑吲哚‑3‑亚甲基)‑1,3‑噻唑烷‑4‑酮类衍生物及其合成方法和应用
|
|
SG11201609981RA
(en)
|
2014-06-04 |
2016-12-29 |
Thomas Helledays Stiftelse För Medicinsk Forskning |
Mth1 inhibitors for treatment of inflammatory and autoimmune conditions
|
|
CA2949785A1
(en)
|
2014-06-04 |
2015-12-10 |
Thomas Helledays Stiftelse For Medicinsk Forskning |
Mth1 inhibitors for treatment of cancer
|
|
US10077277B2
(en)
|
2014-06-11 |
2018-09-18 |
Incyte Corporation |
Bicyclic heteroarylaminoalkyl phenyl derivatives as PI3K inhibitors
|
|
TW201613925A
(en)
|
2014-07-10 |
2016-04-16 |
Incyte Corp |
Imidazopyrazines as LSD1 inhibitors
|
|
TWI687419B
(zh)
|
2014-07-10 |
2020-03-11 |
美商英塞特公司 |
作為ｌｓｄ１抑制劑之咪唑并吡啶及咪唑并吡嗪
|
|
US9758523B2
(en)
|
2014-07-10 |
2017-09-12 |
Incyte Corporation |
Triazolopyridines and triazolopyrazines as LSD1 inhibitors
|
|
WO2016007722A1
(en)
|
2014-07-10 |
2016-01-14 |
Incyte Corporation |
Triazolopyridines and triazolopyrazines as lsd1 inhibitors
|
|
CA2954681A1
(en)
*
|
2014-07-31 |
2016-02-04 |
Merck Patent Gmbh |
Indolizine derivatives and their use in neurodegenerative diseases
|
|
JP2017523211A
(ja)
*
|
2014-08-04 |
2017-08-17 |
ドレクセル ユニバーシティ |
新規化合物およびそれを用いてｉｌ−１ｒ媒介性の疾患または障害を処置するかまたは寛解させる方法
|
|
JO3589B1
(ar)
|
2014-08-06 |
2020-07-05 |
Novartis Ag |
مثبطات كيناز البروتين c وطرق استخداماتها
|
|
CN107250113B
(zh)
|
2014-10-07 |
2019-03-29 |
弗特克斯药品有限公司 |
囊性纤维化跨膜传导调节蛋白的调节剂的共晶
|
|
US10851105B2
(en)
|
2014-10-22 |
2020-12-01 |
Incyte Corporation |
Bicyclic heterocycles as FGFR4 inhibitors
|
|
GB201419579D0
(en)
|
2014-11-03 |
2014-12-17 |
Iomet Pharma Ltd |
Pharmaceutical compound
|
|
TWI568737B
(zh)
|
2014-11-05 |
2017-02-01 |
達特神經科學（開曼）有限責任公司 |
作為ｐｄｅ２抑制劑之經取代的５－甲基－［１，２，４］三唑并［１，５－ａ］嘧啶－２－胺化合物
|
|
EP3239147B9
(en)
|
2014-12-25 |
2020-01-08 |
Ono Pharmaceutical Co., Ltd. |
Quinoline derivative
|
|
GB201501302D0
(en)
|
2015-01-27 |
2015-03-11 |
Ostara Biomedical Ltd |
Embryo implantation
|
|
US9580423B2
(en)
|
2015-02-20 |
2017-02-28 |
Incyte Corporation |
Bicyclic heterocycles as FGFR4 inhibitors
|
|
MA41551A
(fr)
|
2015-02-20 |
2017-12-26 |
Incyte Corp |
Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
|
|
ES2895769T3
(es)
|
2015-02-20 |
2022-02-22 |
Incyte Corp |
Heterociclos bicíclicos como inhibidores de FGFR
|
|
CN117736209A
(zh)
|
2015-02-27 |
2024-03-22 |
因赛特控股公司 |
Pi3k抑制剂的盐及其制备方法
|
|
EP4591936A3
(en)
|
2015-03-23 |
2025-10-15 |
Tianli Biotech Pty Ltd |
Treatment of respiratory diseases
|
|
EP3626720A1
(en)
|
2015-04-03 |
2020-03-25 |
Incyte Corporation |
Heterocyclic compounds as lsd1 inhibitors
|
|
MA41898A
(fr)
|
2015-04-10 |
2018-02-13 |
Hoffmann La Roche |
Dérivés de quinazolinone bicyclique
|
|
WO2016176420A1
(en)
*
|
2015-04-30 |
2016-11-03 |
Musc Foundation For Research Development |
Oxindole compounds and pharmaceutical compositions thereof
|
|
WO2016183063A1
(en)
|
2015-05-11 |
2016-11-17 |
Incyte Corporation |
Crystalline forms of a pi3k inhibitor
|
|
US9732097B2
(en)
|
2015-05-11 |
2017-08-15 |
Incyte Corporation |
Process for the synthesis of a phosphoinositide 3-kinase inhibitor
|
|
GB201508276D0
(en)
*
|
2015-05-14 |
2015-06-24 |
Electrophoretics Ltd |
A casein kinase 1 delta inhibitor
|
|
GB201509134D0
(en)
|
2015-05-28 |
2015-07-15 |
Electrophoretics Ltd |
Biomolecules involved in Alzheimer's disease
|
|
JP6707630B2
(ja)
*
|
2015-06-01 |
2020-06-10 |
バンタム、ファーマシューティカル、リミテッド、ライアビリティー、カンパニーＢａｎｔａｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌ， Ｌｌｃ |
置換ピラゾールおよびピロール化合物、および翻訳開始の阻害およびこれらに関連する疾患および障害の治療のためにこれらを用いる方法
|
|
WO2016202758A1
(en)
|
2015-06-18 |
2016-12-22 |
Bayer Pharma Aktiengesellschaft |
Substituted 2-(1h-pyrazol-1-yl)-1h-benzimidazole compounds
|
|
WO2016202756A1
(en)
|
2015-06-18 |
2016-12-22 |
Bayer Pharma Aktiengesellschaft |
Substituted 2-(1h-pyrazol-1-yl)-1h-benzimidazole compounds
|
|
JP2018525345A
(ja)
*
|
2015-07-01 |
2018-09-06 |
ノースウェスタン ユニバーシティ |
置換キナゾリン化合物及びグルコセレブロシダーゼ活性の調節のためのその使用
|
|
WO2017000277A1
(en)
*
|
2015-07-01 |
2017-01-05 |
Merck Sharp & Dohme Corp. |
Substituted triazolo bicycliccompounds as pde2 inhibitors
|
|
KR102710120B1
(ko)
|
2015-08-12 |
2024-09-27 |
인사이트 홀딩스 코포레이션 |
Lsd1 저해제의 염
|
|
CN105061462B
(zh)
*
|
2015-08-18 |
2017-05-24 |
沈阳药科大学 |
含有酰胺的四氢苯并[4,5]噻吩并[2,3‑d]嘧啶类化合物及其应用
|
|
UA123362C2
(uk)
*
|
2015-09-04 |
2021-03-24 |
Ф. Хоффманн-Ля Рош Аг |
Феноксиметильні похідні
|
|
KR20180052635A
(ko)
|
2015-09-18 |
2018-05-18 |
가켄 세이야쿠 가부시키가이샤 |
바이아릴 유도체 및 이를 포함하는 약제
|
|
CR20180072A
(es)
|
2015-09-24 |
2018-02-26 |
Hoffmann La Roche |
Nuevos compuestos biciclicos como inhibidores de atx
|
|
AU2016328535A1
(en)
|
2015-09-24 |
2017-11-09 |
F. Hoffmann-La Roche Ag |
Bicyclic compounds as ATX inhibitors
|
|
KR20180053408A
(ko)
|
2015-09-24 |
2018-05-21 |
에프. 호프만-라 로슈 아게 |
이중 오토탁신(atx)/탄산 무수화효소(ca) 억제제로서의 신규한 이환형 화합물
|
|
CR20180057A
(es)
|
2015-09-24 |
2018-04-02 |
Hoffmann La Roche |
Nuevos compuestos biciclicos como inhibidores duales de atx/ca.
|
|
EP3359526A4
(en)
*
|
2015-10-05 |
2019-04-03 |
The Trustees of Columbia University in the City of New York |
ACTIVATORS OF AUTOPHAGIC RIVER AND PHOSPHOLIPASE D AND PURIFICATION OF PROTEIN AGGREGATES INCLUDING TAU AND TREATMENT OF PROTEINOPATHIES
|
|
GB201517523D0
(en)
|
2015-10-05 |
2015-11-18 |
Ostara Biomedical Ltd |
Methods and compositions for managing reproduction
|
|
WO2017063966A1
(en)
|
2015-10-13 |
2017-04-20 |
Bayer Pharma Aktiengesellschaft |
Substituted 2-(1h-pyrazol-1-yl)-benzothiazole compounds
|
|
HK1256751A1
(zh)
|
2015-11-02 |
2019-10-04 |
Janssen Pharmaceutica Nv |
[1，2，4]三唑并[1，5-a]嘧啶-7-基化合物
|
|
CA3007783C
(en)
*
|
2015-12-07 |
2021-06-08 |
Hinova Pharmaceuticals Inc. |
Quinoline compounds, preparation methods thereof, and uses thereof as urate transporter inhibitor drug
|
|
WO2017106367A1
(en)
*
|
2015-12-15 |
2017-06-22 |
D.E. Shaw Research, Llc |
Method of treating neurodegenerative disorders by rescuing alpha-synuclein toxicity
|
|
CN107840826B
(zh)
*
|
2016-09-19 |
2021-07-09 |
西华大学 |
1h-吲唑类衍生物及其作为ido抑制剂的用途
|
|
WO2017133258A1
(zh)
*
|
2016-02-04 |
2017-08-10 |
西华大学 |
1h-吲唑类衍生物及其作为ido抑制剂的用途
|
|
CN107033087B
(zh)
*
|
2016-02-04 |
2020-09-04 |
西华大学 |
1h-吲唑-4-胺类化合物及其作为ido抑制剂的用途
|
|
PE20190377A1
(es)
|
2016-04-22 |
2019-03-08 |
Incyte Corp |
Formulaciones de un inhibidor de lsd 1
|
|
US10774064B2
(en)
|
2016-06-02 |
2020-09-15 |
Cadent Therapeutics, Inc. |
Potassium channel modulators
|
|
EA202092442A3
(ru)
|
2016-06-07 |
2021-08-31 |
Джакобио Фармасьютикалс Ко., Лтд. |
Новые гетероциклические производные, применимые в качестве ингибиторов shp2
|
|
EP3474856B1
(en)
|
2016-06-24 |
2022-09-14 |
Infinity Pharmaceuticals, Inc. |
Combination therapies
|
|
SG11201811161YA
(en)
|
2016-07-14 |
2019-01-30 |
Pfizer |
Novel pyrimidine carboxamides as inhibitors of vanin-1 enzyme
|
|
WO2018030762A1
(ko)
*
|
2016-08-09 |
2018-02-15 |
세종대학교산학협력단 |
Ampk 억제기능에 기반한 뇌졸중 치료용 약학적 조성물
|
|
JP7471818B2
(ja)
|
2016-08-18 |
2024-04-22 |
ヴィダック ファーマ リミテッド |
ピペラジン誘導体、医薬組成物、及びその使用方法
|
|
CR20220309A
(es)
|
2016-09-02 |
2022-09-16 |
Cyclerion Therapeutics Inc |
Estimuladores de sgc
|
|
CN106432235B
(zh)
*
|
2016-10-19 |
2018-02-02 |
南通大学 |
靶向CDK和DNA的β‑咔啉衍生物及其制备方法和医药用途
|
|
US11970486B2
(en)
|
2016-10-24 |
2024-04-30 |
Janssen Pharmaceutica Nv |
Compounds and uses thereof
|
|
CN109937202B
(zh)
|
2016-11-02 |
2022-12-30 |
詹森药业有限公司 |
作为pde2抑制剂的[1,2,4]三唑并[1,5-a]嘧啶化合物
|
|
MA46690A
(fr)
*
|
2016-11-02 |
2019-09-11 |
Janssen Pharmaceutica Nv |
Composés de [1,2,4]triazolo [1,5-a]pyrimidine en tant qu'inhibiteurs de pde2
|
|
MY193511A
(en)
*
|
2016-11-02 |
2022-10-17 |
Janssen Pharmaceutica Nv |
[1,2,4]triazolo[1,5-a]pyrimidine derivatives as pde2 inhibitors
|
|
US11008325B2
(en)
|
2016-11-14 |
2021-05-18 |
Virginia Commonwealth University |
Inhibitors of cancer invasion, attachment, and/or metastasis
|
|
WO2018094106A2
(en)
|
2016-11-16 |
2018-05-24 |
University Of South Florida |
ALLOSTERIC ANTAGONISTS OF GPRC6a AND THEIR USE IN MITIGATING PROTEINOPATHIES
|
|
AU2018205275B2
(en)
|
2017-01-06 |
2024-05-02 |
Janssen Pharmaceutica Nv |
Methods for the treatment of neurological disorders
|
|
CN110494136A
(zh)
*
|
2017-01-10 |
2019-11-22 |
瑞士苏黎世联邦理工学院 |
细胞保护性化合物及其用途
|
|
CN106748969B
(zh)
*
|
2017-01-23 |
2019-06-18 |
南阳师范学院 |
一种n-(4-苄基哌啶基)-阿魏酰胺化合物、制备方法及其用途
|
|
CN106831573B
(zh)
*
|
2017-01-23 |
2019-05-24 |
南阳师范学院 |
(n-1,2,3,4-四氢异喹啉基)-阿魏酰胺化合物、制备方法及其应用
|
|
JP6997197B2
(ja)
|
2017-01-23 |
2022-01-17 |
カデント セラピューティクス，インコーポレーテッド |
カリウムチャネルモジュレーター
|
|
JP6605763B2
(ja)
|
2017-01-26 |
2019-11-13 |
小野薬品工業株式会社 |
キノリン誘導体のエタンスルホン酸塩
|
|
US11072599B2
(en)
|
2017-02-01 |
2021-07-27 |
Biotheryx, Inc. |
Pyrazole compounds and uses thereof
|
|
CN109700794B
(zh)
*
|
2017-03-01 |
2021-01-08 |
浙江大学 |
腙结构类型雄激素受体拮抗剂及其应用
|
|
CN110382484B
(zh)
|
2017-03-16 |
2022-12-06 |
豪夫迈·罗氏有限公司 |
新的作为atx抑制剂的二环化合物
|
|
SG11201908560SA
(en)
|
2017-03-16 |
2019-10-30 |
Hoffmann La Roche |
Heterocyclic compounds useful as dual atx/ca inhibitors
|
|
DK3448859T3
(da)
|
2017-03-20 |
2019-09-23 |
Forma Therapeutics Inc |
Pyrrolopyrrolsammensætninger som pyruvatkinase- (pkr) aktivatorer
|
|
KR102317480B1
(ko)
|
2017-03-23 |
2021-10-25 |
자코바이오 파마슈티칼스 컴퍼니 리미티드 |
Shp2 억제제로서 유용한 신규한 헤테로환형 유도체
|
|
EP3615529B1
(en)
|
2017-04-26 |
2024-06-05 |
Basilea Pharmaceutica International AG, Allschwil |
Processes for the preparation of furazanobenzimidazoles and crystalline forms thereof
|
|
US11136312B2
(en)
*
|
2017-05-12 |
2021-10-05 |
Board of Trustees of the Southern Illinois University |
3,4,5-trisubstituted-1,2,4-triazoles and 3,4,5-trisubstituted-3-thio-1,2,4-triazoles and uses thereof
|
|
AR111960A1
(es)
|
2017-05-26 |
2019-09-04 |
Incyte Corp |
Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
|
|
JOP20190282A1
(ar)
|
2017-06-09 |
2019-12-05 |
Novartis Ag |
مركبات وتركيبات لحث تكوّن الغضاريف
|
|
AU2018285449A1
(en)
*
|
2017-06-14 |
2019-12-19 |
European Molecular Biology Laboratory |
Benzofuran amides and heteroaromatic analogues thereof for use in therapy
|
|
WO2018237145A1
(en)
|
2017-06-21 |
2018-12-27 |
Mitokinin, Inc. |
Compositions and methods using the same for treatment of neurodegenerative and mitochondrial disease
|
|
GB201710851D0
(en)
*
|
2017-07-06 |
2017-08-23 |
Galápagos Nv |
Novel compounds and pharmaceutical compositions thereof for the treatment of fibrosis
|
|
US10357489B2
(en)
|
2017-07-10 |
2019-07-23 |
Celgene Corporation |
Antiproliferative compounds and methods of use thereof
|
|
WO2019014352A1
(en)
|
2017-07-11 |
2019-01-17 |
Vertex Pharmaceuticals Incorporated |
CARBOXAMIDES AS INHIBITORS OF SODIUM CHANNELS
|
|
US12221430B2
(en)
|
2017-09-11 |
2025-02-11 |
Hodogaya Chemical Co., Ltd. |
Compound having pyrimidine ring structure and organic electroluminescence device
|
|
WO2019055877A1
(en)
|
2017-09-15 |
2019-03-21 |
Forma Therapeutics, Inc. |
TETRAHYDROIMIDAZO QUINOLINE COMPOSITIONS AS INHIBITORS OF CBP / P300
|
|
US11826363B2
(en)
|
2017-10-13 |
2023-11-28 |
Ono Pharmaceutical Co., Ltd. |
Therapeutic agent for solid cancers, which comprises Axl inhibitor as active ingredient
|
|
CA3079081A1
(en)
|
2017-10-19 |
2019-04-25 |
Michael D. Bartberger |
Benzimidazole derivatives and their uses
|
|
US11873298B2
(en)
|
2017-10-24 |
2024-01-16 |
Janssen Pharmaceutica Nv |
Compounds and uses thereof
|
|
CN111788186A
(zh)
*
|
2017-12-21 |
2020-10-16 |
格利亚制药股份公司 |
治疗包括痴呆的神经紊乱的组合物和方法
|
|
US20200325148A1
(en)
*
|
2017-12-21 |
2020-10-15 |
Gliapharm Sa |
Compositions and methods of treatment for neurological disorders comprising motor neuron diseases
|
|
MA52422A
(fr)
|
2018-02-27 |
2021-01-06 |
Incyte Corp |
Imidazopyrimidines et triazolopyrimidines en tant qu'inhibiteurs a2a/a2b
|
|
WO2019173437A1
(en)
*
|
2018-03-06 |
2019-09-12 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Positive allosteric modulators of dopamine 1 receptor and method of use thereof
|
|
EP3543231A1
(en)
*
|
2018-03-19 |
2019-09-25 |
ETH Zurich |
Compounds for treating cns- and neurodegenerative diseases
|
|
AU2019238326B2
(en)
|
2018-03-23 |
2025-03-06 |
Janssen Pharmaceutica Nv |
Compounds and uses thereof
|
|
SG11202010882XA
(en)
|
2018-05-04 |
2020-11-27 |
Incyte Corp |
Salts of an fgfr inhibitor
|
|
SI3788047T1
(sl)
|
2018-05-04 |
2024-11-29 |
Incyte Corporation |
Trdne oblike inhibitorja fgfr in postopki priprave le-teh
|
|
TWI815887B
(zh)
*
|
2018-05-15 |
2023-09-21 |
美商愛彼特生物製藥股份有限公司 |
經取代的2,2'-雙嘧啶基化合物、其類似物及其使用方法
|
|
MX2020012376A
(es)
|
2018-05-18 |
2021-03-09 |
Incyte Corp |
Derivados de pirimidina fusionados como inhibidores de los receptores de adenosina a2a/a2b.
|
|
PE20211208A1
(es)
|
2018-06-01 |
2021-07-05 |
Incyte Corp |
Regimen de dosificacion para el tratamiento de trastornos relacionados con pi3k
|
|
GB201810092D0
(en)
|
2018-06-20 |
2018-08-08 |
Ctxt Pty Ltd |
Compounds
|
|
GB201810581D0
(en)
|
2018-06-28 |
2018-08-15 |
Ctxt Pty Ltd |
Compounds
|
|
AU2019295790B2
(en)
|
2018-06-29 |
2023-07-13 |
Forma Therapeutics, Inc. |
Inhibiting creb binding protein (CBP)
|
|
MA53097A
(fr)
|
2018-07-05 |
2021-05-12 |
Incyte Corp |
Dérivés de pyrazine fusionnés en tant qu'inhibiteurs d'a2a/a2b
|
|
EP3833344A4
(en)
*
|
2018-08-06 |
2022-07-06 |
The Board of Trustees of the Leland Stanford Junior University |
2-ARYLBENZIMIDAZOLES USEFUL AS PPARGC1A ACTIVATORS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES
|
|
NZ773164A
(en)
|
2018-08-29 |
2025-07-25 |
Chemocentryx Inc |
Combination therapy using c-c chemokine receptor 4 (ccr4) antagonists and one or more immune checkpoint inhibitors
|
|
US10968200B2
(en)
|
2018-08-31 |
2021-04-06 |
Incyte Corporation |
Salts of an LSD1 inhibitor and processes for preparing the same
|
|
WO2020051206A1
(en)
*
|
2018-09-04 |
2020-03-12 |
Brown University |
Compositions and methods for the modulation of crfbp and the treatment of alcoholism
|
|
AU2019344897B2
(en)
|
2018-09-18 |
2024-01-18 |
Nikang Therapeutics, Inc. |
Tri-substituted heteroaryl derivatives AS SRC homology-2 phosphatase inhibitors
|
|
WO2020061378A1
(en)
|
2018-09-19 |
2020-03-26 |
Forma Therapeutics, Inc. |
Treating sickle cell disease with a pyruvate kinase r activating compound
|
|
JP7450610B2
(ja)
|
2018-09-19 |
2024-03-15 |
ノヴォ・ノルディスク・ヘルス・ケア・アーゲー |
ピルビン酸キナーゼｒの活性化
|
|
WO2020063760A1
(en)
|
2018-09-26 |
2020-04-02 |
Jacobio Pharmaceuticals Co., Ltd. |
Novel heterocyclic derivatives useful as shp2 inhibitors
|
|
MX2021004647A
(es)
|
2018-10-22 |
2021-08-16 |
Novartis Ag |
Formas cristalinas de moduladores de los canales de potasio.
|
|
KR102880470B1
(ko)
*
|
2018-10-23 |
2025-11-03 |
다이이찌 산쿄 가부시키가이샤 |
바이아릴 유도체
|
|
WO2020093098A1
(en)
|
2018-11-07 |
2020-05-14 |
The University Of Melbourne |
Novel compounds for the treatment of respiratory diseases
|
|
CN109503563B
(zh)
*
|
2018-12-10 |
2020-05-12 |
济南大学 |
多功能乙酰胆碱酯酶抑制剂及其应用
|
|
KR102128509B1
(ko)
*
|
2018-12-19 |
2020-07-01 |
한국과학기술연구원 |
말단 아민기에 아릴 또는 헤테로아릴기가 치환된 신규한 히드라존 유도체 및 이의 용도
|
|
KR20210112317A
(ko)
*
|
2019-01-04 |
2021-09-14 |
벨부르크 랩스, 엘엘씨 |
치료제로서의 cgas 활성 억제제
|
|
US12440481B2
(en)
|
2019-01-10 |
2025-10-14 |
Vertex Pharmaceuticals Incorporated |
Esters and carbamates as modulators of sodium channels
|
|
WO2020146682A1
(en)
|
2019-01-10 |
2020-07-16 |
Vertex Pharmaceuticals Incorporated |
Carboxamides as modulators of sodium channels
|
|
KR20220007845A
(ko)
|
2019-01-24 |
2022-01-19 |
유마니티 테라퓨틱스, 인크. |
화합물 및 이의 용도
|
|
TWI829857B
(zh)
|
2019-01-29 |
2024-01-21 |
美商英塞特公司 |
作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶
|
|
WO2020185532A1
(en)
|
2019-03-08 |
2020-09-17 |
Incyte Corporation |
Methods of treating cancer with an fgfr inhibitor
|
|
WO2020190791A1
(en)
|
2019-03-15 |
2020-09-24 |
Forma Therapeutics, Inc. |
Inhibiting cyclic amp-responsive element-binding protein (creb)
|
|
CN114072395A
(zh)
*
|
2019-04-26 |
2022-02-18 |
新基公司 |
杂环化合物及其治疗蠕虫感染和疾病的用途
|
|
UY38687A
(es)
|
2019-05-17 |
2023-05-15 |
Novartis Ag |
Inhibidores del inflamasoma nlrp3, composiciones, combinaciones de los mismos y métodos para su uso
|
|
FI3986890T3
(fi)
|
2019-06-18 |
2024-01-15 |
Pfizer |
Bentsisoksatsolisulfonamidijohdannaisia
|
|
US11591329B2
(en)
|
2019-07-09 |
2023-02-28 |
Incyte Corporation |
Bicyclic heterocycles as FGFR inhibitors
|
|
WO2021021986A1
(en)
|
2019-07-31 |
2021-02-04 |
Ribon Therapeutics, Inc. |
Heterobicyclic amides as inhibitors of cd38
|
|
RU2746423C2
(ru)
*
|
2019-09-02 |
2021-04-13 |
Общество с ограниченной ответственностью "Научно-исследовательский институт ХимРар" (ООО "НИИ ХимРар") |
Ингибитор вируса гепатита В (ВГВ)
|
|
MX2022003254A
(es)
|
2019-09-19 |
2022-04-18 |
Forma Therapeutics Inc |
Composiciones activadoras de piruvato cinasa r (pkr).
|
|
WO2021067374A1
(en)
|
2019-10-01 |
2021-04-08 |
Incyte Corporation |
Bicyclic heterocycles as fgfr inhibitors
|
|
US11607416B2
(en)
|
2019-10-14 |
2023-03-21 |
Incyte Corporation |
Bicyclic heterocycles as FGFR inhibitors
|
|
US11566028B2
(en)
|
2019-10-16 |
2023-01-31 |
Incyte Corporation |
Bicyclic heterocycles as FGFR inhibitors
|
|
EA202192047A1
(ru)
|
2019-11-13 |
2021-12-08 |
Юманити Терапьютикс, Инк. |
Соединения и их применение
|
|
EP4066832A4
(en)
|
2019-11-14 |
2024-01-03 |
Zincure Corp. |
Pharmaceutical composition for treating multiple sclerosis on basis of ampk inhibitory function and zinc homeostasis control function
|
|
EP4069696A1
(en)
|
2019-12-04 |
2022-10-12 |
Incyte Corporation |
Tricyclic heterocycles as fgfr inhibitors
|
|
WO2021113462A1
(en)
|
2019-12-04 |
2021-06-10 |
Incyte Corporation |
Derivatives of an fgfr inhibitor
|
|
PH12022551379A1
(en)
|
2019-12-06 |
2023-05-03 |
Vertex Pharma |
Substituted tetrahydrofurans as modulators of sodium channels
|
|
WO2021146424A1
(en)
|
2020-01-15 |
2021-07-22 |
Incyte Corporation |
Bicyclic heterocycles as fgfr inhibitors
|
|
AR122711A1
(es)
*
|
2020-06-25 |
2022-09-28 |
Alchemedicine Inc |
COMPUESTO HETEROCÍCLICO COMO INHIBIDOR DE CASEÍNA QUINASA 1d Y/O QUINASA 5 TIPO RECEPTOR DE ACTIVINA
|
|
WO2022035805A1
(en)
*
|
2020-08-10 |
2022-02-17 |
Dana-Farber Cancer Institute, Inc. |
Substituted 1,2,4-oxadiazoles as small molecule inhibitors of ubiquitin-specific protease 28
|
|
EP4214199A1
(en)
*
|
2020-09-17 |
2023-07-26 |
JANSSEN Pharmaceutica NV |
Casein kinase 1 delta modulators
|
|
US11795168B2
(en)
|
2020-09-23 |
2023-10-24 |
Forma Therapeutics, Inc. |
Inhibiting cyclic amp-responsive element-binding protein (CREB) binding protein (CBP)
|
|
US11801243B2
(en)
|
2020-09-23 |
2023-10-31 |
Forma Therapeutics, Inc. |
Bromodomain inhibitors for androgen receptor-driven cancers
|
|
GB202101734D0
(en)
*
|
2021-02-08 |
2021-03-24 |
Cerevance Inc |
Novel Compounds
|
|
JP2024508794A
(ja)
|
2021-02-19 |
2024-02-28 |
スドー バイオサイエンシーズ リミテッド |
Ｔｙｋ２阻害剤およびその使用
|
|
EP4294808A1
(en)
|
2021-02-19 |
2023-12-27 |
Sudo Biosciences Limited |
Tyk2 inhibitors and uses thereof
|
|
US12128035B2
(en)
|
2021-03-19 |
2024-10-29 |
Novo Nordisk Health Care Ag |
Activating pyruvate kinase R
|
|
WO2022221170A1
(en)
|
2021-04-12 |
2022-10-20 |
Incyte Corporation |
Combination therapy comprising an fgfr inhibitor and a nectin-4 targeting agent
|
|
EP4293023A4
(en)
*
|
2021-04-21 |
2024-12-18 |
Changchun Genescience Pharmaceutical Co., Ltd. |
Imidazole-containing condensed ring derivative, preparation method therefor, and application thereof in medicine
|
|
DK4347031T3
(da)
|
2021-06-04 |
2025-12-01 |
Vertex Pharma |
N-(hydroxyalkyl-(hetero)aryl)-tetrahydrofuran-carboxamider som modulatorer af natriumkanaler
|
|
WO2022261159A1
(en)
|
2021-06-09 |
2022-12-15 |
Incyte Corporation |
Tricyclic heterocycles as fgfr inhibitors
|
|
WO2022261160A1
(en)
|
2021-06-09 |
2022-12-15 |
Incyte Corporation |
Tricyclic heterocycles as fgfr inhibitors
|
|
US20250011319A1
(en)
*
|
2021-10-15 |
2025-01-09 |
Lomond Therapeutics, Inc. |
SUBSTITUTED 1H-PYRAZOLO [4,3-c] QUINOLINES, METHODS OF PREPARATION, AND USE THEREOF
|
|
CN115466211B
(zh)
*
|
2022-06-09 |
2024-02-23 |
中国人民解放军空军军医大学 |
一种n-苯基喹啉-4-胺类化合物及其应用
|
|
CN119497615A
(zh)
*
|
2022-07-14 |
2025-02-21 |
上海日馨医药科技股份有限公司 |
Tpk激动剂及使用其治疗神经退行性疾病的方法
|
|
UY40374A
(es)
|
2022-08-03 |
2024-02-15 |
Novartis Ag |
Inhibidores de inflamasoma nlrp3
|
|
WO2024083150A1
(zh)
*
|
2022-10-19 |
2024-04-25 |
长春金赛药业有限责任公司 |
一种nk3r拮抗剂的晶型及其制备方法和应用
|
|
EP4646263A1
(en)
*
|
2023-01-20 |
2025-11-12 |
Allianthera (Suzhou) Biopharmaceutical Co., Ltd. |
Sprk1 inhibitors and methods of use
|
|
EP4660182A1
(en)
*
|
2023-01-30 |
2025-12-10 |
Eurofarma Laboratórios S.A. |
Nav1.7- and/or nav1.8-inhibiting aryl pyridine compounds, processes for the preparation thereof, compositions, uses, methods for treatment using same, and kits
|
|
AR131690A1
(es)
*
|
2023-01-30 |
2025-04-23 |
Eurofarma Laboratorios S A |
COMPUESTOS FENÓLICOS BLOQUEADORES DE Nav 1.7 Y/O Nav 1.8, SUS PROCESOS DE OBTENCIÓN, SUS COMPOSICIONES, SUS USOS, LOS MÉTODOS DE TRATAMIENTO DE LOS MISMOS Y LOS KITS
|
|
CN118666857B
(zh)
*
|
2024-06-26 |
2025-02-25 |
江西农业大学 |
一种喹啉类化合物及其在农用杀菌剂中的应用
|
|
CN119060061B
(zh)
*
|
2024-08-26 |
2025-09-16 |
浙江师范大学 |
一类苯并嘧啶硫醚类化合物作为sting蛋白小分子抑制剂的应用
|